ES2189234T3 - Nuevos derivados de taxano. - Google Patents

Nuevos derivados de taxano.

Info

Publication number
ES2189234T3
ES2189234T3 ES98943019T ES98943019T ES2189234T3 ES 2189234 T3 ES2189234 T3 ES 2189234T3 ES 98943019 T ES98943019 T ES 98943019T ES 98943019 T ES98943019 T ES 98943019T ES 2189234 T3 ES2189234 T3 ES 2189234T3
Authority
ES
Spain
Prior art keywords
group
substituted
carbon atoms
unsubstituted alkyl
hydrogen atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98943019T
Other languages
English (en)
Inventor
Atsuhiro Kabushiki Kaisha Abe
Hideaki Kabushiki Kaisha Shimizu
Seigo Kabushiki Kaisha Sawada
Takanori Kabushiki Kaisha Ogawa
Hiroshi Kabushiki Kaish Nagata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yakult Honsha Co Ltd
Original Assignee
Yakult Honsha Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yakult Honsha Co Ltd filed Critical Yakult Honsha Co Ltd
Application granted granted Critical
Publication of ES2189234T3 publication Critical patent/ES2189234T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Un derivado de taxano representado por la siguiente fórmula (1): **(Fórmula)** [en la que A representa un grupo -N NR1 (en el que R1 representa un átomo de hidrógeno o un grupo alquilo sustituido o sin sustituir que tiene de 1 a 10 átomos de carbono o un grupo benciloxicarbonilo) o un grupo -N -R2(en el que R2 representa un grupo amino, un grupo mono- o dialquilamino siendo el alquilo un grupo alquilo sustituido o sin sustituir que tiene de 1 a 10 átomos de carbono o un grupo amino cíclico), X representa un grupo alquilo sustituido o sin sustituir que tiene de 1 a 10 átomos de carbono, un grupo piridilo, un grupo tienilo, un grupo furilo, un grupo cicloalquiloxi de C3-C6, un grupo isopropiloxi, un grupo neopentiloxi o un grupo terc-amiloxi, Y representa un átomo de hidrógeno o un grupo tri(alquil(C1-C6)sililo, Ac representa un grupo acetilo, Bz representa un grupo benzoílo, y Ph representa un grupo fenilo] o una sal del mismo.
ES98943019T 1997-09-17 1998-09-17 Nuevos derivados de taxano. Expired - Lifetime ES2189234T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9251804A JPH1192468A (ja) 1997-09-17 1997-09-17 新規なタキサン誘導体

Publications (1)

Publication Number Publication Date
ES2189234T3 true ES2189234T3 (es) 2003-07-01

Family

ID=17228181

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98943019T Expired - Lifetime ES2189234T3 (es) 1997-09-17 1998-09-17 Nuevos derivados de taxano.

Country Status (14)

Country Link
US (1) US6136808A (es)
EP (1) EP1022277B1 (es)
JP (1) JPH1192468A (es)
KR (1) KR100514809B1 (es)
CN (1) CN100369908C (es)
AT (1) ATE229012T1 (es)
AU (1) AU730174B2 (es)
BR (1) BR9812218A (es)
CA (1) CA2302445C (es)
DE (1) DE69809959T2 (es)
DK (1) DK1022277T3 (es)
ES (1) ES2189234T3 (es)
PT (1) PT1022277E (es)
WO (1) WO1999014209A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU758418B2 (en) * 1997-12-19 2003-03-20 Kabushiki Kaisha Yakult Honsha Taxane derivatives
KR100603877B1 (ko) * 1999-05-28 2006-07-25 브리스톨-마이어즈 스퀴브 컴페니 디알킬디클로로실란을 사용한 파클리탁셀의 반합성
DE60134814D1 (de) 2000-02-02 2008-08-28 Univ Florida State Res Found C10-carbamoyloxysubstituierte taxane als antitumormittel
IL145635A0 (en) * 2000-02-02 2002-06-30 Univ Florida State Res Found Taxane formulations having improved solubility
US6649632B2 (en) * 2000-02-02 2003-11-18 Fsu Research Foundation, Inc. C10 ester substituted taxanes
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
CA2354471A1 (en) * 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 ester substituted taxanes
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
ATE444062T1 (de) 2002-06-26 2009-10-15 Medigene Ag Herstellung einer kationisch liposomalen zubereitung, einen lipophilen wirkstoff enthaltend
CA2525647A1 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
PE20050693A1 (es) 2004-02-13 2005-09-27 Univ Florida State Res Found Taxanos sustituidos con esteres de ciclopentilo en c10
TW200640447A (en) * 2005-02-14 2006-12-01 Univ Florida State Res Found C10 cyclopropyl ester substituted taxane compositions
US7772177B2 (en) 2005-05-18 2010-08-10 Aegera Therapeutics, Inc. BIR domain binding compounds
WO2007107305A2 (en) 2006-03-22 2007-09-27 Medigene Ag Treatment of triple receptor negative breast cancer
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
KR100847331B1 (ko) * 2006-12-14 2008-07-21 한미약품 주식회사 도세탁셀의 제조방법 및 이에 사용되는 중간체
WO2009145981A1 (en) * 2008-03-31 2009-12-03 Florida State University Research Foundation, Inc. C(10) ethyl ester and c(10) cyclopropyl ester substituted taxanes
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
HUE047004T2 (hu) * 2008-06-16 2020-04-28 Pfizer Hatóanyaggal töltött polimer nanorészecskék és eljárások elõállításukra és alkalmazásukra
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS
KR101014438B1 (ko) * 2008-09-26 2011-02-14 동아제약주식회사 탁산 유도체의 제조방법
EP2534170B1 (en) 2010-02-12 2017-04-19 Pharmascience Inc. Iap bir domain binding compounds
WO2013119864A1 (en) 2012-02-07 2013-08-15 University Of Central Florida Research Foundation, Inc. Increasing taxane sensitivity in cancer cells
US9181343B2 (en) 2012-07-19 2015-11-10 Redwood Bioscience Inc. Antibody specific for CD22 and methods of use thereof
KR20150083121A (ko) 2012-11-12 2015-07-16 레드우드 바이오사이언스 인코포레이티드 화합물, 및 컨쥬게이트의 제조방법
DK3300745T3 (da) 2013-02-15 2019-11-04 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
KR20150135332A (ko) 2013-03-14 2015-12-02 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 미토콘드리아 알데히드 탈수소효소-2 조절인자들 및 이들의 사용 방법
CN105744935B (zh) 2013-11-27 2022-09-30 雷德伍德生物科技股份有限公司 肼基-吡咯并化合物及用于生成缀合物的方法
PL3107899T3 (pl) 2014-02-19 2021-01-25 Aviv Therapeutics, Inc. Policykliczne amidy wiążące mitochondrialną dehydrogenazę aldehydową-2 (aldh2) i ich zastosowanie w leczeniu nowotworów
PE20161211A1 (es) 2014-03-21 2016-11-27 Abbvie Inc Anticuerpos y conjugados de anticuerpo y farmaco anti-egfr
US10300070B2 (en) 2014-03-27 2019-05-28 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
EP3231421A1 (en) 2016-04-11 2017-10-18 Greenaltech, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
PT3463308T (pt) 2016-06-01 2022-03-11 Servier Ip Uk Ltd Formulações de óxido de polialquileno asparaginase e métodos de fabrico e utilização do mesmo
AU2017279554A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
US20200002432A1 (en) 2016-06-08 2020-01-02 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
CR20180603A (es) 2016-06-08 2019-07-29 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco
EP3468993A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CA3027046A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
EP3565530A4 (en) 2017-01-05 2020-07-01 Syncore Biotechnology Co., Ltd. TREATMENT OF LATIVAL CANCER
AU2018211081A1 (en) 2017-01-18 2019-07-18 Bioatla, Inc. Chimeric antigen receptors against Axl or Ror2 and methods of use thereof
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
WO2020206033A1 (en) 2019-04-02 2020-10-08 Kenjockety Biotechnology, Inc. Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
AU2021214370A1 (en) 2020-01-29 2022-08-18 Kenjockety Biotechnology, Inc. Anti-MDR1 antibodies and uses thereof
AU2021284240A1 (en) 2020-06-04 2022-12-08 Kenjockety Biotechnology, Inc. Anti-ABCG2 antibodies and uses thereof
WO2021247423A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
EP4208483A1 (en) 2020-09-02 2023-07-12 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
US20240010747A1 (en) 2020-11-13 2024-01-11 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
KR20240116829A (ko) 2021-12-13 2024-07-30 윌리엄 로버트 아라툰 리빙 트러스트 데이티드 어거스트 29, 2016 항-abcb1 항체
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5243045A (en) * 1991-09-23 1993-09-07 Florida State University Certain alkoxy substituted taxanes and pharmaceutical compositions containing them
US5227400A (en) * 1991-09-23 1993-07-13 Florida State University Furyl and thienyl substituted taxanes and pharmaceutical compositions containing them
US5250683A (en) * 1991-09-23 1993-10-05 Florida State University Certain substituted taxanes and pharmaceutical compositions containing them
FR2687151B1 (fr) * 1992-02-07 1994-03-25 Rhone Poulenc Rorer Sa Nouveaux derives de la baccatine iii et de la desacetyl-10 baccatine iii, leur preparation et les compositions pharmaceutiques qui les contiennent.
JPH08253465A (ja) * 1995-03-17 1996-10-01 Dai Ichi Seiyaku Co Ltd 四環性化合物
FR2742753B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
KR100476247B1 (ko) * 1996-07-15 2005-03-10 가부시키가이샤 야쿠루트 혼샤 탁산 유도체 및 그를 함유하는 의약
US6017935A (en) * 1997-04-24 2000-01-25 Bristol-Myers Squibb Company 7-sulfur substituted paclitaxels

Also Published As

Publication number Publication date
DE69809959D1 (de) 2003-01-16
AU730174B2 (en) 2001-03-01
DK1022277T3 (da) 2003-01-06
DE69809959T2 (de) 2003-07-24
CN100369908C (zh) 2008-02-20
KR100514809B1 (ko) 2005-09-13
ATE229012T1 (de) 2002-12-15
CN1270587A (zh) 2000-10-18
US6136808A (en) 2000-10-24
EP1022277A1 (en) 2000-07-26
EP1022277A4 (en) 2000-07-26
WO1999014209A1 (fr) 1999-03-25
CA2302445A1 (en) 1999-03-25
KR20010023937A (ko) 2001-03-26
CA2302445C (en) 2008-04-29
AU9095098A (en) 1999-04-05
BR9812218A (pt) 2000-07-18
JPH1192468A (ja) 1999-04-06
PT1022277E (pt) 2003-04-30
EP1022277B1 (en) 2002-12-04

Similar Documents

Publication Publication Date Title
ES2189234T3 (es) Nuevos derivados de taxano.
CO5700733A2 (es) Acidos aminocarboxilicos sustituidos
BRPI0510598A (pt) compostos de amida de aril ou heteroaril substituìdos
CO5140119A1 (es) 3-substituido-n-(hetero)arilalquil-pirrolidinas
WO2003106628A3 (en) BENZFIAZEPINE F1F0 ATP HYDROLASE MITOCHONDRIAL INHIBITORS AND METHODS OF INHIBITING F1F0 ATP HYDROLASE
AR040787A1 (es) 6-alcoxi-piridopirimidinas
FI924932A0 (fi) Aromatiska amidinderivat och salter daerav samt deras framstaellning
ES2196186T3 (es) Inhibidores de protein-isoprenil-transferasas.
HRP20021038B1 (en) Compounds with a sulfonamide group and pharmaceutical compositions that contain these compounds
ATE302001T1 (de) Stabilisierte askorbinsäurederivate
MXPA03011324A (es) Preparacion de derivados de indolo o benzotienilo novedosa y uso de los mismos como inhibidores de proteina de preniltransferasa.
AR041867A1 (es) Agente para prevenir o tratar neuropatia
IS6309A (is) Kínasólínafleiður
DE69012515D1 (de) Haarfärbemittel.
RU93005332A (ru) Производные 4,1-бензоксазепина, фармацевтическая композиция, способ лечения
IS2123B (is) Indól-2,3-díon-3-oxíms afleiður
CO5140127A1 (es) Derivados de 2-fenilpiran-4-ona
EA200500191A1 (ru) Кристаллический 2,5-дион-3-(1-метил-1h-индол-3-ил)-4-[1-(пиридин-2-илметил)пиперидин-4-ил]-1h-индол-3-ил]-1h-пирролмоногидрохлорид
CO5590914A2 (es) Derivados de 5-(piridin-3-il)-1-azabiciclo [3.2.1] octano
EA200300010A1 (ru) Производные 2-аминотиазолина и их применение в качестве ингибиторов no-синтазы
HUP0302504A2 (hu) Peptid-deformiláz inhibitorok alkalmazása bakteriálisfertőzések kezelésére
ATE430476T1 (de) Schlammbehandlung
BR9814987A (pt) "oximas substituìdas como antagonistas da neurocinina"
NO990285L (no) Tienylcykloheksan-derivater for tienylcykloheksyl-syntese
DE60106293D1 (de) Verfahren zur inhibierung von katarakten